文献速递妇科

临床计算器重新定义高危早期卵巢癌的预后并有望指导辅助治疗

Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting.
PubMed 文献 · Gynecol Oncol · 2022-08-31

基于美国国家癌症数据库2005至2015年8188例I-II期高危卵巢癌患者,利用Cox回归构建临床评分计算器,将患者分为低、中、高危组,5年总生存率分别为92%、82%、66%,10年总生存率分别为85%、67%、44%。化疗可改善高危组5年及10年总生存率,中危组仅5年总生存率改善,低危组无改善。

要点

  • 临床计算器基于年龄、分期、组织学、分级、肿瘤大小、盆腔及腹主动脉旁淋巴结清扫数目、恶性腹水及CA125构建。
  • 高危组化疗后5年总生存率从56%升至73%,10年总生存率从34%升至48%(p均<0.001)。
  • 低危组化疗未改善5年或10年总生存率(93%对92%,p=1.0;86%对84%,p=0.99)。

核心结论

  • 高危早期卵巢癌患者的预后具有异质性,该计算器可能有助于围绕潜在治疗获益进行以患者为中心的咨询。

研究设计与样本

  • 回顾性分析美国国家癌症数据库2005至2015年I-II期高危卵巢癌患者数据,使用Cox回归构建临床评分,并采用倾向评分加权调整化疗与未化疗患者间的差异。

主要发现

  • 8188例患者中,6915例(84%)接受化疗,1273例(16%)未接受化疗。
  • 计算器将患者分为低、中、高危组,5年总生存率分别为92%、82%、66%,10年总生存率分别为85%、67%、44%。
  • 高危组化疗改善5年总生存率(56%至73%,p<0.001)和10年总生存率(34%至48%,p<0.001)。
  • 中危组化疗改善5年总生存率(80%至85%,p=0.01),但10年总生存率无显著改善(66%至66%,p=0.13)。
  • 低危组化疗未改善5年总生存率(93%至92%,p=1.0)或10年总生存率(86%至84%,p=0.99)。

临床怎么用

  • 作者认为该计算器可能有助于围绕潜在治疗获益进行以患者为中心的咨询。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the utility of a clinical calculator to redefine prognosis and need for chemotherapy among patients with early-stage high-risk epithelial ovarian cancer. METHODS: Data were abstracted for stage I-II, high-risk ovarian cancer from the National Cancer Database from years 2005 to 2015. Based on demographic, pathologic, surgical, and laboratory characteristics, a clinical score was developed using Cox regression. Propensity score weighting was used to adjust for differences between patients who did and did not receive chemotherapy. RESULTS: Of 8188 patients with early-stage high-risk ovarian cancer, 6915 (84%) did and 1273 (16%) did not receive chemotherapy. A clinical calculator was created utilizing age, stage, histology, grade, tumor size, number of pelvic and paraaortic lymph nodes examined, the presence of malignant ascites, and CA125. The calculator divided patients into low, moderate, and high-risk groups with 5-year OS (overall survival) of 92%, 82%, and 66%, and 10-year OS of 85%, 67%, and 44%, respectively. Chemotherapy improved 5-year OS and 10-year OS in the high-risk group (56% to 73%; p < 0.001, 34% to 48%; p < 0.001). The moderate risk group had improved 5-year OS (80% to 85%; p = 0.01) but not 10-year OS (66% to 66%; p = 0.13). Chemotherapy did not improve 5-year or 10-year OS in low-risk patients (93% to 92%, p = 1.0, 86% to 84%, p = 0.99). CONCLUSIONS: The prognosis among high-risk early-stage ovarian cancer patients is heterogeneous. This calculator may aid in patient-centered counseling regarding potential treatment benefits.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bui A, Gehrig PA, Ghamande S, et al. Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting. Gynecol Oncol. 2022. PMID: 36055814. doi:10.1016/j.ygyno.2022.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。